In a new study, John P.A. Ioannidis has calculated the IFR for Covid-19 based on available studies which evaluate seroprevalence, i.e. determine how many people in population samples have developed antibodies for the virus:
https://www.medrxiv.org/content/10.1101 ... 1.full.pdfI am sad that some may declare Ionannidis, Professor of Medicine, of Health Research and Policy and of Biomedical Data Science, at Stanford University School of Medicine and a Professor, by courtesy, of Statistics at Stanford University School of Humanities and Sciences, who is a widely respected authority in his field, to be “my” expert. Ionannidis is a person who has stuck his neck out and, without using inflammatory language, suggested the portrayal of the pandemic by big pharma and media outlets in its pocket is too alarmist, and given the power that big pharma now wields over academia including the power to destroy academic careers, we must accept that this is a bold move and one whose only motive I believe to be the desire to prevent people from becoming unnecessarily alarmed, and as such this man is everyone’s expert, not just “mine” or “yours”.
What Ionnidis has done in the paper is look for seroprevalence population studies with a sample size of at least 500 and published as peer-reviewed papers or preprints as of May 12, 2020, and twelve such studies were identified as having usable data.
He notes, “Seroprevalence estimates ranged from 0.113% to 25.9% and adjusted seroprevalence estimates ranged from 0.309% to 33%. Infection fatality rates ranged from 0.03% to 0.50% and corrected values ranged from 0.02% to 0.40%."
He sums up the various results, “Interestingly, despite their differences in design, execution, and analysis, most studies provide IFR point estimates that are within a relatively narrow range. Seven of the 12 inferred IFRs are in the range 0.07 to 0.20 (corrected IFR of 0.06 to 0.16) which are similar to IFR values of seasonal influenza. Three values are modestly higher (corrected IFR of 0.25-0.40 in Gangelt, Geneva, and Wuhan) and two are modestly lower than this range (corrected IFR of 0.02-0.03 in Kobe and Oise).”
It is important to note the methodology underlying Ioannides’ study, that of comparing all currently available studies which evaluate seroprevalence, which only started to become available recently. This does not mean that studies based on other methodologies lack value, or that differences between them show there is a lack of consensus in the scientific world. However, I would suggest that the kind of studies he is using, large-scale empirical studies applying rigorous scientific techniques to the study of data collected in the field, are more reliable than earlier studies which were based on far more speculative data.